359
Nasdaq-listed, Root-headquartered global oncology company, Novocure, has entered into a new five-year senior secured credit facility of up to US$400m with funds managed by Pharmakon Advisors. The committed capital will be available to Novocure in four tranches of US$100m.
Pharmakon Advisors is an investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds.
The first US$100m has already been issued, with the second US$100m tranche to be issued by June 30, 2025. An…